WK500B

Overview

WK500B is a potent and orally active BCL6 inhibitor with a K D of 1.61 μM. WK500B engages intracellular BCL6 and disrupts BCL6‑corepressor interactions to reactivate BCL6 target genes. WK500B exerts cytotoxicity against diffuse large B‑cell lymphoma cells and induces apoptosis and cell cycle arrest. WK500B suppresses germinal center formation in C57BL/6 mice and DLBCL tumor growth in SCID xenograft models without observable toxicity. WK500B can be used for the study of diffuse large B‑cell lymphoma (DLBCL).

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Diffuse Large B-cell Lymphoma | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > GPCR/G Protein | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > BCL6 | Products > Signaling Pathways > MDM-2/p53 | Products > Signaling Pathways > Histone Methyltransferase | Products > Signaling Pathways > CXCR

Product Information

• Catalog No.: HY-148640
• CAS No.: 2253985-29-2
• Molecular Formula: C22H23BrFN7O
• Molecular Weight: 500.38
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source